Abstract: Methods of treatment of complement-mediated disorders, in particular disorders associated with over-activity of the complement C3b feedback cycle (for example, age-related macular degeneration (AMI)), using gene therapy is described. According to the methods, levels of complement Factor I are elevated by administration of a recombinant viral vector encoding Factor I such that a therapeutically effective amount of the encoded Factor I is expressed from the vector in the subject. Recombinant viral vectors encoding Factor I, recombinant virus particles encapsidating the vectors, and their use in the methods of treatment, is also described.

Abstract: A computer-implemented method for sampling data from a measurement device for representing uncertainty in measurements made by the measurement device, the method comprising: obtaining a data set comprising time-sequential data elements generated by the measurement device; and: (a) calculating a statistic of a sub-set of data elements consecutive within the data set; (b) comparing the value of the statistic to a reference value; and, (c) if the value of the statistic differs from the reference value by less than a threshold amount, then: modifying the sub-set by appending to the sub-set at least one additional data element which is subsequent to the sub-set; and, repeating steps (a) to (c) for the modified sub-set of data elements; (d) if the value of the statistic differs from the reference value by more than said threshold amount, then: outputting the sub-set collectively as a sample set of data elements generated by the measurement device for representing uncertainty in measurements made by the measurement

Abstract: Aspects of the present disclosure relate to methods of cultivating genetically altered plants with increased activity of one or more of a NODULATION SIGNALING PATHWAY 1 (NSP1) protein or a NODULATION SIGNALING PATHWAY 2 (NSP2) protein that have increased mycorrhization and/or promoted symbiotic responses under high phosphate and/or high nitrate conditions. Further aspects of the present disclosure relate to methods of cultivating genetically altered plants with increased activity of a C-TERMINALLY ENCODED PEPTIDE (CEP peptide) that have increased mycorrhization and/or promoted symbiotic responses under high phosphate and/or high nitrate conditions. In addition, aspects of the present disclosure relate to methods of cultivating these plants that include exogenous application of strigolactones, karrikins, and/or CEP peptides to increase mycorrhization and/or promote symbiotic responses under specific nutrient conditions.

Abstract: A method for computation on distributions of data, the method comprising providing a microarchitecture comprising: a first register containing data items; a second register containing distribution data representing distributions that are uncertainty representations associated with respective said data items; a first arithmetic logic unit for executing arithmetic on data items selected from the first register; a second arithmetic logic unit for executing arithmetic on distribution data selected from the second register; the method comprising the following steps implemented by the microarchitecture: executing, by the first arithmetic logic unit, an arithmetic operation on data items selected from the first register, and outputting the result; executing, by the second arithmetic logic unit, an arithmetic operation on distribution data representing distributions selected from the second register that are associated with the data items selected from the first register, and outputting the result; wherein the arithm

Abstract: This invention relates to collagen biomaterials and methods for manufacturing collagen biomaterials. Method disclosed herein include steps of providing a suspension of insoluble collagen fibres, providing a layer deposition interface and applying an electric field across the suspension to cause electrophoretic deposition of the insoluble collagen fibres at the layer deposition interface. Biomaterials disclosed herein include a layer comprising an array of fibres of collagen, and a layered composite material comprising at least first and second fibrous layers each comprising an array of fibres of collagen, and a shape adapting layer sandwiched between the first and second fibrous layers. Biomaterials as described herein may be useful in a range of tissue engineering and other applications.

Abstract: A microscopic imaging method comprising: illuminating a three-dimensional object with a light sheet generated by an illumination optical system and capturing light-field information of the illuminated object with an imaging optical system.

Abstract: Embodiments of the present techniques provide apparatus and methods for analysing intracoronary images, for example to predict the likelihood of a disease, disease presentation or event, and/or to track performance of a drug or other treatment. The method may comprise: for each image in the set of images of a coronary artery: classifying the image, using a first neural network, for the presence or absence of diseased tissue; when the image is classified as having diseased tissue present, classifying the image, using a second neural network, for the presence or absence of an artefact; determining whether to analyse the image based on the classifying steps; when the image is to be analysed, analysing the image by identifying, using a third neural network, one or more features of interest in a coronary artery tissue; and measuring each identified feature of interest.

Abstract: The invention provides a method of characterising a DNA sample obtained from a tumour, the method including the steps of: determining the value of one or more mutational signature metrics for the sample, wherein the mutational signature metrics are selected from: exposure of one or more mutational signatures of mismatch repair (MMR), similarity between the substitution profile of the sample and that of one or more MMR gene knockouts, the number of repeat mediated indels in the mutational profile of the sample, and the similarity between the repeat mediated deletion profile of the sample and that of one or more MMR gene knockouts; and based on said values of said one or more mutational signature metrics, classifying said sample between a class associated with a high likelihood of being mismatch repair (MMR)-deficient and a class associated with a low likelihood of being MMR-deficient.

Abstract: The present invention relates to synthetic polypeptide compounds which bind to a class A G-protein-coupled receptor, the Apelin receptor. These compounds may act as apelin receptor antagonists. These compounds and compositions comprising them may be useful in the treatment of diseases, such as cancer.

Abstract: Flow apparatuses comprising a separation channel, a downstream flow separator, a detection zone, an observation zone, and a waste channel. The separation channel has first and second flows in contact and allows lateral movement of components between contacting first and second flows. The downstream flow separator is in communication with the separation channel and diverts a part of the first fluid flow, the second fluid flow, or both, from the separation channel. The detection zone comprises a detection channel downstream of and in communication with the flow separator and configured to receive a plurality of diverted flows from the flow separator and a label channel configured to label the diverted flows from the flow separator. The observation zone is configured to record an analytical signal indicative of the quantity and the electrical properties of the component. The waste channel is at the downstream end of the observation zone.

Abstract: A laser device comprises a first optical cavity comprising a first gain medium and a second optical cavity comprising a second gain medium. The first gain medium and the second gain medium generate light at respective different ranges of wavelengths. A synchronizer is optically coupled to both the first optical cavity and the second optical cavity and is configured to synchronize and mode-lock light from the first optical cavity and the second optical cavity. The laser device also includes a first optical filter and a second optical filter to filter the light from the first optical cavity and the second optical cavity respectively to output first filtered light pulses at a first predetermined range of wavelengths and second filtered light pulses at a second predetermined range of wavelengths.

Abstract: The invention relates to the grafting of perennial monocots such as bananas and oil palms. Processes for the production of such plants are disclosed herein.

Abstract: The present application relates to metal-organic framework (MOF) nanoparticles, in particular, coated MOF nanoparticles, methods of manufacturing said coated MOF nanoparticles, and uses of said coated MOF nanoparticles.

Abstract: The invention relates to a polypeptide selected from bone morphogenetic protein 10 (BMP10), or a bone morphogenetic protein 9 (BMP9) variant lacking osteogenic activity, for use in the treatment of a vascular disease or a respiratory disease. The invention also relates to novel BMP9 variants and to pharmaceutical compositions comprising said polypeptides.

Abstract: An electronic stethoscope system comprising a device to capture an acoustic heart signal from a patient and a neural network to classify the data into heart sound categories to provide time series sound category data comprising, for each of a succession of time intervals, category probability data representing a probability of the acoustic signal falling into each of the categories. The stethoscope also includes one or more heart state models each having a sequence of heart cardiac cycle states, a system to fit the time series sound category data to the models and determine timing data for the sequence of heart states and a confidence value for the model fit, and an output to output one or both of a model fit indication dependent upon the confidence value and an indication of the timing data.

Abstract: The present invention provides capsules having a shell of material that comprises an assembly of a protein, and the capsule is optionally provided with a network of material within the shell that is an assembly of the protein. The assembly of the protein is obtained or obtainable by the aggregation of the protein, optionally together with another protein. The assembly is a non-covalent assembly of a protein.

Abstract: We disclose herein a hetero-structure comprising: a curved material; at least one layer of a first material rolled around the curved material; at least one intermediate layer rolled on the at least one layer of the first material; and at least one layer of a second material rolled around the at least one intermediate layer.

Abstract: Provided are a compound of the formula: (5-(2-(4-((3,5-difluoro-4-(trifluoromethoxy)benzyl)amino)butoxy)ethoxy)benzo[c][2,6]naphthyridine-8-carboxylic acid) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the above compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

Abstract: A microfluidic sensor comprising: a first substrate; a second substrate; a cavity formed between the first substrate and the second substrate, the cavity comprising a reservoir portion and a channel portion extending from the reservoir portion; a capacitive element disposed between the first substrate and the second substrate, the capacitive element being at least partially disposed in the channel portion of the cavity; and a dielectric sensing liquid provided in the reservoir portion. Upon application of a force to the first substrate adjacent the reservoir portion, the reservoir portion is configured to deform and displace the sensing liquid along the channel portion, so as to change the capacitance of the capacitive element within the channel portion.

Abstract: A method is disclosed of manufacturing a semiconductor structure comprising an (001) oriented zincblende structure group III-nitride layer, such as GaN. The layer is formed on a 3C-SiC layer on a silicon substrate. A nucleation layer is formed, recrystallized and then the zincblende structure group III-nitride layer is formed by MOVPE at temperature T3 in the range 750-1000° C., to a thickness of at least 0.5?. There is also disclosed a corresponding semiconductor structure comprising a zincblende structure group III-nitride layer which, when characterized by XRD, shows that the substantial majority, or all, of the layer is formed of zincblende structure group III-nitride in preference to wurtzite structure group III-nitride.